Other substances

GSK-LSD1

A lysine-specific demethylase 1 inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Other treatment

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

GSK-LSD1 is a lysine-specific demethylase 1 (LSD1) inhibitor. The phosphorylated form of LSD1 was reported to be responsible for NF-κB p65 stabilization controlling the pro-inflammatory cytokine gene expression (Hong et al., 2020).

GSK-LSD1 on PubChem

Synonyms

N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine

 

Structure image - GSK-LSD1

C1CNCCC1N[C@@H]2C[C@H]2C3=CC=CC=C3

Supporting references

Link Tested on Impact factor Notes Publication date
GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro
Severe severity Small molecule In vitro 		COVID-19 patient peripheral blood mononuclear cells 13.49

The S112-phosphorylation of LSD1 protein was found to be more abundant in peripheral blood mononuclear cells (PBMCs) of severe COVID-19 patients compared to non-severe ones. The treatment of PBMCs with GSK-LSD1 decreased the proportion of phosphorylated S112 residues within the LSD1 pool, decreased the expression of nuclear NF-κB p65, and improved the cell viability of severe COVID-19 PBMCs. NF-κB p65's methylation was found to be maintained and its stability was reduced. GSK-LSD1 also reduced the expression of NF-κB-dependent pro-inflammatory cytokine genes in PBMCs from severe COVID-19 patients.

 Nov/17/2020
Export (.csv)